Please login to the form below

Not currently logged in
Email:
Password:

betrixaban

This page shows the latest betrixaban news and features for those working in and with pharma, biotech and healthcare.

ViiV’s two-drug HIV combo backed by CHMP

ViiV’s two-drug HIV combo backed by CHMP

There was bad news for three other companies, with the CHMP issuing negative opinions for Portola’s Dexxience (betrixaban) for the prevention of venous thromboembolism, Radius International’s osteoporosis candidate Eladynos

Latest news

  • Bad news for Portola as CHMP considers Factor Xa drugs Bad news for Portola as CHMP considers Factor Xa drugs

    Bad news for Portola as CHMP considers Factor Xa drugs. The committee are ‘unlikely’to adopt a positive opinion for betrixaban. ... for betrixaban, its oral, once-daily Factor Xa inhibitor, as well as antidote drug andexanet alfa.

  • Archive listing

    The committee are ‘unlikely’to adopt a positive opinion for betrixaban. .

  • Merck collaborate over betrixaban

    In return for an exclusive worldwide license to betrixaban, Merck will pay Portola an initial fee of $50m. ... for additional royalties and to co-promote betrixaban with Merck in the US.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Betrixaban. Betrixaban (Portola Pharmaceuticals) is a long-acting oral factor Xa inhibitor that entered phase III trial development for VTE prevention in medically ill patients in March 2012. ... Promising phase II results of betrixaban for VTE

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics